|
|
Article: AMERICAN ASSOCIATION FOR CANCER RESEARCH ISIS PRESENTS INTERIM ISIS 2503 PHASE II PANCREATIC CANCER DATA.(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- April 11, 2002
- Author:
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Isis Pharmaceuticals Inc. presented positive data from a planned interim analysis of a pancreatic cancer Phase II trial evaluating ISIS 2503 in combination with gemcitabine.
Clinical investigators found pancreatic cancer patients survived six months or longer when taking ISIS 2503 and gemcitabine, surpassing the primary endpoint of the study. The trial was designed to test improvement in patient survival and in patient response rates. The trial is being conducted by the North Central Cancer Trial Group.
The criteria for success at the interim analysis were the survival of nine or more patients for at least six months. The analysis was performed after ...